14 results about "Chimeric gene" patented technology

The invention discloses a method for improving the inductivity and genetic transformation efficiency of hairy roots of toona ciliata. According to the method, agrobacterium rhizogenes carrying RUBY-TcGRF8-GIF2 chimeric protein are injected into stems and petioles of aseptic seedlings of the toona ciliata, and the TcGRF8-GIF2 chimeric gene is over-expressed, so that the induction efficiency and the genetic transformation efficiency of the toona ciliata hairy roots are remarkably improved, and the transformation period of the toona ciliata hairy roots is remarkably shortened. Specifically, after overexpression of the TcGRF8-GIF2 gene, the induction time of the hairy roots is shortened from 70 days of a RUBY-XbaI no-load plasmid control group to 25 days, the induction rate and conversion rate of the hairy roots mediated by agrobacterium tumefaciens are improved, the operation efficiency of genetic transformation of the toona ciliata is effectively improved, and the method has important significance for promoting genetic improvement of the toona ciliata.

The present disclosure provides methods for inducing callus formation and plant regeneration from isolated protoplasts of grape. This technology allows for the production of non-chimeric gene edits in grape plants by allowing the delivery of DNA through the plant cell membrane with the recovery of whole plants from a single edited cell.

Provided is an Alzheimer's disease rat model or a tissue or cell thereof, which comprises a chimeric APP gene encoding a modified APP and use thereof.

The current invention provides an improved process of the manufacture of pharmaceutical products comprising proteins, useful for the prevention or treatment of leishmaniasis. The pharmaceutical composition comprises a protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.

The present invention relates to a chimeric protein consisting of a specific region of a protein selected from the group consisting of LIC 10123, LIC 13059, LIC 13050, LIC 12615, LIC 11636, LIC 11352, LIC 11122, LIC 11089, LIC 10713 and LIC 13434, which is demonstrated to be conservative and present on the surface of LIC 10123, LIC 13059, LIC 13050, LIC 12615, LIC 11636, LIC 11352, LIC 11122, LIC 11089, LIC 10713 and LIC 13434, wherein the specific region consists of the amino acid sequence defined by SEQ ID NO: 2, 4, 6, 7, 9, 11, 13, 14, 16, 18, 20 and 22 The invention further relates to a host microbial cell comprising a chimeric gene consisting of the nucleotide sequence shown in SEQ ID NO: 25, said chimeric gene and an expression cassette. In addition, the invention relates to a method for obtaining said chimeric protein and a leptospirosis serological diagnostic kit comprising the chimeric protein of the invention. Furthermore, the present invention relates to an in vitro method for the early serological diagnosis of leptospirosis and the use of said chimeric protein for the early serological diagnosis of leptospirosis by detecting IgM and / or IgG antibodies in a serum sample from a patient suspected of having leptospirosis.

The current invention provides an improved manufacturing process, in particular improved downstream processing, of pharmaceutical products especially comprising proteins, useful for the prevention or treatment of leishmaniosis. The pharmaceutical composition may comprise a protein chimera Q, which is the product of a chimeric gene encoding the antigenic determinants of four proteins of Leishmania infantum.

The invention relates to a tobacco CMS-S type cytoplasmic male sterility gene orf291 and application thereof in tobacco breeding, which are characterized in that the tobacco CMS-S type cytoplasmic male sterility gene orf291 is obtained by sequencing mitochondrial genomes of a tobacco sterile plant MSK326 and a fertile plant K326, and screening conditions that a candidate sterile gene sequence length exists, a transmembrane structure domain and a chimeric gene exist in the mitochondrial genomes of the sterile plant but do not exist in the mitochondrial genomes of the sterile plant, and the like. Finally, it is clear that the tobacco CMS-S type sterile gene orf291 is the only tobacco sterile gene meeting the same conditions, and a gene expression analysis result shows that orf291 is massively expressed in a tobacco sterile plant MSK326 and is not expressed in a fertile plant K326. The clear sequence of the CMS-S type sterile gene orf291 provides a necessary targeting target for subsequently creating a tobacco restorer line through targeted knockout of the gene and preventing and treating tobacco mitochondrial diseases, and has important application potential in tobacco crossbreeding.

The present invention relates to a recombinant oleaginous yeast cell having at least one CEX1 gene disruption, comprising chimeric gene constructs, each of said chimeric gene constructs comprising a yeast-expressible promoter and a 3' end region comprising transcription termination and polyadenylation signals functioning in a yeast cell, wherein said chimeric gene constructs allow for overexpression of DGA1, ACC1, MCE2, and ACL genes, said ACL gene being ACL1 and / or ACL2 gene. In a second aspect, the invention relates to a method for producing lipids using said transformed oleaginous yeast cell. The invention further pertains to lipids obtainable by the method, a composition comprising said lipids, a composition comprising transformed oleaginous yeast cell, and a food product obtainable therefrom.

The application provides a construction method and application of a humanized hNOTCH3 gene animal model, the model expresses a human-animal chimeric NOTCH3 gene in vivo, and the chimeric NOTCH3 protein expressed includes a human NOTCH3 protein extracellular main functional domain, and can be used for NOTCH3 gene function research, screening and evaluation of human NOTCH3 targeted drugs and therapies. The animal model prepared by using the application can be used for quickly establishing more different hNOTCH3 gene humanized disease animal models of NOTCH3 gene mutations, drug screening for human NOTCH3 target sites, pharmacodynamic research, related nervous system diseases and tumor treatment and the like, accelerates a new drug research and development process, saves time and cost, and reduces drug development risks.

Disclosed herein include methods, compositions, and kits suitable for use in generation of genome-expanded organisms comprising, e.g., a chimeric genome. In some embodiments, the methods, systems and nucleic acid compositions include systems comprising a donor cell comprising one or more components of a delivery module and a recipient cell comprising one or more components of an integrator module. In some embodiments, the methods, systems and nucleic acid compositions comprise polynucleotides encoding one or more components of a delivery module, and one or more components of an integrator module.

Disclosed in the present invention are a method for preparing a functional P2X1 membrane protein monoclonal antibody and the use thereof. The method comprises: immunizing mice by means of preparing a human P2X1 protein having a natural spatial structure and activity; preparing eight functional P2X1 monoclonal antibodies by using a monoclonal antibody preparation technique, and selecting two clones with a relatively good functionality to perform gene sequencing so as to obtain functional variable region sequences; and selecting the clone with the best function, and replacing a murine Fc fragment thereof with a human Fc fragment to prepare one semi-humanized chimeric genetically engineered antibody. Function verification shows that the engineered antibody exhibits comparable functional activity to the original murine antibody, thus indicating that there is a specific correlation between the sequence of the variable region F(ab)2 of the engineered antibody and the functional activity of the engineered antibody. The functional P2X1 monoclonal antibody has the effects of inhibiting calcium ion influx in P2X1-overexpressing cells, inhibiting cell dysfunction caused by P2X1 overactivation, restoring the chemotactic function of neutrophil granulocytes inhibited by endotoxin, improving the survival rate of septic mice, inhibiting the division and proliferation of tumor cells, and inhibiting tumor growth in tumor-bearing mice.

The invention discloses a GRF4-GIF1 chimeric gene for improving genetic transformation and gene editing efficiency of an oat immature embryo as well as a vector and application of the GRF4-GIF1 chimeric gene. The GRF4-GIF1 chimeric gene is constructed into a transformation vector or a gene editing vector, so that the synergistic expression of the chimeric gene in recipient cells is realized. The method comprises the following steps: firstly, stripping an oat immature embryo, performing agrobacterium infection and co-culture, and then transferring into a recovery culture medium for culture; then, transferring well-grown calluses to a screening culture medium for screening, sequentially transferring the screened positive calluses into a differentiation and proliferation culture medium and a rooting culture medium, and culturing to obtain differentiated seedlings with certain root length; and finally, hardening seedlings, and culturing in vermiculite to obtain complete regenerated plants. According to the method, the GRF4-GIF1 chimeric gene is integrated in the carrier construction stage, and the immature embryo of the oat is selected as the explant, so that the genetic transformation efficiency of the oat is effectively improved, and the gene editing of the quality character of the feeding oat is successfully completed.

The application belongs to the technical field of biological medicine, and particularly relates to a porcine reproductive and respiratory syndrome nucleic acid vaccine adjuvant for activating Toll-like receptor 3, and a preparation method and application thereof. The porcine reproductive and respiratory syndrome nucleic acid vaccine adjuvant contains a recombinant sequence of a chimeric conservative sequence of 3'UTR in a PRRSV genome, which is taken as a scaffold of human serine tRNA. The chimeric conservative sequence of 3'UTR in the PRRSV genome is a sequence with a similarity of more than 90% to SEQ ID NO. 1, and the recombinant sequence is a sequence with a similarity of more than 70% to SEQ ID NO. 2. The nucleic acid vaccine adjuvant produced by the application has low toxicity and low immunogenicity, can activate TLR3, and can induce high-level antibody and cellular immune responses.